Meag Munich Ergo’s Alexion Pharmaceuticals ALXN Stock Holding History

Meag Munich Ergo’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,616	Closed	-$388K	–	514
2019 Q4	$388K	Sell	3,616 -11,178	-76%	-$1.2M	0.04%	314
2019 Q3	$1.44M	Buy	14,794 +6,323	+75%	+$713K	0.07%	284
2019 Q2	$1.07M	Hold	8,471	–	–	0.08%	247
2019 Q1	$1.13M	Sell	8,471 -1,541	-15%	-$192K	0.09%	233
2018 Q4	$985K	Buy	+10,012	New	+$1.18M	0.12%	245
2018 Q3	–	Sell	-10,449	Closed	-$1.28M	–	428
2018 Q2	$1.28M	Buy	+10,449	New	+$1.22M	0.08%	239
2018 Q1	–	Sell	-21,713	Closed	-$2.63M	–	525
2017 Q4	$2.63M	Sell	21,713 -18,756	-46%	-$2.28M	0.1%	242
2017 Q3	$5.62M	Buy	40,469 +14,956	+59%	+$2.03M	0.23%	132
2017 Q2	$3.12M	Buy	25,513 +1,107	+5%	+$129K	0.14%	176
2017 Q1	$2.97M	Buy	24,406 +480	+2%	+$61.9K	0.12%	208
2016 Q4	$2.97M	Buy	+23,926	New	+$2.93M	0.14%	180

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Meag Munich Ergo's ALXN Position: Q1 2020 in Review

Meag Munich Ergo sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 3,616 shares — an estimated $388K sold.

Meag Munich Ergo first reported a position in ALXN in Q4 2016 and held it in 11 quarters. The position peaked at $5.62M in Q3 2017. 654 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

Meag Munich Ergo reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Meag Munich Ergo sold 3,616 Alexion Pharmaceuticals shares in Q1 2020, an estimated $388K.
Meag Munich Ergo first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 11 quarters.
Meag Munich Ergo's Alexion Pharmaceuticals position peaked at $5.62M in Q3 2017.
654 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Meag Munich Ergo's 13F filing for Q1 2020, filed 23 Apr 2020.